QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Diaz-Flores, E. Articles by Shannon, K. Search for Related Content PubMed PubMed Citation Articles by Diaz-Flores, E. Articles by Shannon, K. Related Content Cancer and Disease Models Signal Transduction Related Article Social Bookmarking                   What's this?

PERSPECTIVE

Targeting oncogenic Ras

Department of Pediatrics, University of California, San Francisco, California 94143, USA

The first 100 words of the full text of this article appear below.

Reversing the consequences of oncogenic Ras is a fundamental problem in cancer therapeutics. Somatic RAS mutations are highly prevalent in many human cancers that respond poorly to current treatments, including carcinomas of the lung, pancreas, and colon; melanoma; and myeloid leukemia (for review, see Schubbert et al. 2007). At first glance, oncogenic Ras is an appealing target for rational drug discovery as the mutant protein is a membrane-associated signaling molecule that is expressed at robust levels in primary tumor cells. However, targeting oncogenic Ras is extremely challenging in practice due to the nature of the Ras cycle and the . . . [Full Text of this Article]

	Oncogenic Ras: meek or macho?

 

	Oncogenic Ras in context

 

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis

Brooke Ancrile, Kian-Huat Lim, and Christopher M. Counter
Genes & Dev. 2007 21: 1714-1719. [Abstract] [Full Text] [PDF]